MedTrace Logo

Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment

NCT05695638 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2024-01-31

No results posted yet for this study

Summary

Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region.

Treatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.

Conditions

  • Solid Tumor, Unspecified, Adult
  • Haematological Malignancy

Sponsors & Collaborators

  • Morten Ladekarl

    lead OTHER

Principal Investigators

  • Morten Ladekarl, MD, DMSCi · Department of Oncology, Aalborg University Hospital, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2030-05-31
Completion
2035-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05695638 on ClinicalTrials.gov